Dyadic International Inc. (DYAI) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Dyadic International Inc. (DYAI) dropped -8.40% to $0.36, trading at 2% of its 52-week range ($0.34 – $1.6). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
JUPITER, Fla., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the
Manufacturing complex drugs can be expensive. One company believes it has found a solution.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -11.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on DYAI today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for DYAI. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Dyadic International Inc. (DYAI) ranks #879 by composite RQD confidence (33/100, grade E) and #860 by equity capitalization ($14.5M). Within this direct 5-issuer industry benchmark cohort, DYAI leads on earnings valuation at N/A trailing P/E, while DYAI leads on capital efficiency and profitability with -35.0% ROIC and 24.9% gross margin. SCLX currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with DYAI at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DYAI
ACTIVE
Dyadic International Inc. | E | 33/100 | — | 24.9% | -35.0% | -8.40% | $14.5M | Benchmark Subject |
| BCDA BioCardia Inc. | D | 49/100 | — | — | -35.0% | -2.26% | $14.0M | /bcda-vs-dyai → |
| ATYR aTyr Pharma Inc. | D | 44/100 | — | — | -35.0% | +4.56% | $13.5M | /atyr-vs-dyai → |
| PLUR Pluri Inc. | D- | 39/100 | — | 49.0% | -35.0% | -2.44% | $16.1M | /plur-vs-dyai → |
| SCLX Scilex Holding Company | D+ | 52/100 | — | 96.0% | -35.0% | -1.43% | $17.5M | /sclx-vs-dyai → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Dyadic International Inc. (DYAI) reported GAAP revenue of $3.1M (-11.6% vs. FY2024 revenue of $3.5M , and +6.6% cumulative change since FY2023) , GAAP net income of -$7.4M, operating cash flow of -$5.7M, and free cash flow of -$5.7M (-43.5% YoY). On the balance sheet, DYAI closed FY2025 with $9.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $3.1M | -$7.4M | -$5.7M | -$5.7M | $9.9M | — |
| FY2024 (FY) | 2024-12-31 | $3.5M | -$5.8M | -$4.0M | -$4.0M | $9.9M | — |
| FY2023 (FY) | 2023-12-31 | $2.9M | -$6.8M | -$6.7M | -$6.7M | — | — |
As of 2026-11-01, Dyadic International Inc. (NASDAQ: DYAI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.36 (-8.40% 1D, market cap $14.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DYAI ranks #879 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), DYAI carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 24.9%, and ROIC of -35.0%. By comparison, BCDA (BioCardia Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC -35.0%, cap $14.0M) and ATYR (aTyr Pharma Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $13.5M). Among the 5-stock peer group, DYAI leads on earnings multiple (N/A) while DYAI leads on capital efficiency (-35.0% ROIC).
Per DYAI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001213809), Dyadic International Inc. generated $3.1M in revenue (-11.6% YoY), -$7.4M in net income, and -$5.7M in free cash flow against $9.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
DYAI last traded at $0.36 (-8.40% on volume of 79,378 shares), positioning the stock -23.40% below its 50-day simple moving average ($0.47) and -52.63% below its 200-day simple moving average ($0.76). Across its 52-week range of $0.34 to $1.60, DYAI sits at the 1.6% percentile with a 14-day RSI of 38.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.40).
Why DYAI Stock dropped -8.40% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.